Sir, Cobicistat is an inhibitor of cytochrome P450 (CYP) 3A enzymes that has been marketed in some countries as a pharmacokinetic enhancer. It has a lower potential for drug interactions than ritonavir, due to its more selective inhibition of CYP3A and lower likelihood for enzymatic induction. 1 Here, we carried out a pharmacokinetic survey in HIV-infected patients switching from darunavir/ritonavir (800/100 mg daily) to darunavir/cobicistat (800/150 mg daily) and given dolutegravir (50 mg daily) as part of their ART.
A consecutive series of HIV-infected patients undergoing therapeutic drug monitoring (TDM) of dolutegravir and darunavir plasma trough concentrations before (visit 1) and after (visit 2) the switch from ritonavir to cobicistat were considered. The second TDM assessment was performed at least 10 days after the switch from ritonavir to cobicistat to ensure steady-state conditions. Collected blood samples were taken 24 h after the last drug intake (a time window of +20 min was considered acceptable), immediately before drug administration. Adherence of patients to therapy was verified through direct questioning during every outpatient visit. Data on self-reporting adherence were matched with data from our pharmacy department to verify that patients have accepted the package with the antiretroviral dose required to cover fully the time between two visits. Only patients with high adherence to antiretroviral medications (.95% of the doses) were considered in the present study. Drug concentrations were assessed by an HPLC method with UV detection previously developed in our laboratory. 2 Comparisons between the two visits were performed by paired t-tests. Data are given as mean + SD.
Approval by the Ethics Committee was deemed unnecessary because, under Italian law, such an approval is required only in the hypothesis of prospective clinical trials on medical products for clinical use (art. 6 and art. 9, leg. decree 211/2003). This retrospective research was conducted on data collected for clinical purposes. All data used in the study were previously anonymized, according to the requirements set by Italian Data Protection Code (leg. decree 196/2003) and by the general authorizations issued by the Data Protection Authority. Written informed consent for medical procedures/interventions performed for routine treatment purposes was collected for each patient.
Patients (n " 12) were all Caucasians, highly pretreated, mainly males (80%), with mean age of 54 + 6 years and with good viroimmunological status (CD4 cell count 650 + 399 cells/mm 3 , viral load ,37 copies/mL). As shown in Figure 1 , the switch from ritonavir to cobicistat resulted in a highly significant increase in dolutegravir trough concentrations (from 599 + 317 to 1149 + 605 ng/mL, !107%, P , 0.001) in all but one patients, whereas no difference in darunavir trough concentrations was observed (from 2033 + 976 to 1979 + 940 ng/mL, !3%, P " 0.754). The second visit was performed at 79 + 62 days after the first TDM assessment. No significant increment in serum creatinine concentrations was recorded between visit 1 and 2 months later at visit 2 (1.14 + 0.33 mg/dL and 1.22 + 0.29 mg/dL, respectively, P " 0.655); similarly no major variations in the other haematochemical and clinical parameters were observed (data not shown).
We confirmed in a real-life setting that the switch from ritonavir to cobicistat resulted in a comparable boosting effect on darunavir exposure. 3 Moreover, we extended previous findings by documenting that cobicistat significantly increased dolutegravir trough concentrations. Given the limited contribution of CYP3A isoforms on dolutegravir metabolism, a direct role of cobicistat on increased dolutegravir bioavailability is unlikely. 4 Therefore, a major role of ritonavir on reduced dolutegravir disposition may be predicted. Indeed, it has been hypothesized that ritonavir could potentially decrease dolutegravir concentrations by the induction of glucuronidation. 5, 6 Accordingly, the switch to cobicistat, by removing the ritonavir-mediated induction of dolutegravir metabolism, is expected to increase dolutegravir exposure. To our knowledge, ours is the first study confirming, in HIV-infected patients, the validity of this assumption. On the other hand, the possibility that the observed pharmacokinetic interaction between dolutegravir and the boosting agents may be driven at least in part by increased dolutegravir absorption mediated by a higher degree of inhibition of cobicistat on intestinal efflux transporters cannot be definitely ruled out. 7 Interestingly, concomitant administration of dolutegravir and cobicistat had no effect on serum creatinine concentrations, suggesting that this combined administration may not result in addictive renal toxicity at least in the short-term. 8 The limited number of patients and the brief follow-up do not allow us to draw any conclusions on the other, less frequent, dolutegravir-related adverse events (i.e. gastrointestinal or neurological complications). However, a potential increase in exposure-related dolutegravir toxicity in cobicistat-treated patients seems unlikely in consideration of the recently reported optimal safety outcome of dolutegravir plus atazanavir combination, despite the observed 2-fold higher dolutegravir concentrations compared with other regimens. 9 The use of cobicistat in dolutegravir-based antiretroviral regimens might become eventually relevant in selected clinical conditions, such as in poorly compliant patients, when the dose of dolutegravir should be doubled in patients carrying resistance to integrase inhibitors, or when medications known to reduce dolutegravir absorption (i.e. mineral supplements) are coadministered. 10 In conclusion, ritonavir and cobicistat not only differ in terms of selectivity for cytochrome inhibition but also for patterns of modulation of phase II metabolic enzymes and drug transporters. These differences may have potential clinical implications when HIV-infected patients are switched from one to another booster, dependent on which medications are coadministered. 11 
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